Literature DB >> 29870068

J wave syndromes as a cause of malignant cardiac arrhythmias.

José M Di Diego1, Charles Antzelevitch1,2,3.   

Abstract

The J wave syndromes, including the Brugada (BrS) and early repolarization (ERS) syndromes, are characterized by the manifestation of prominent J waves in the electrocardiogram appearing as an ST segment elevation and the development of life-threatening cardiac arrhythmias. BrS and ERS differ with respect to the magnitude and lead location of abnormal J waves and are thought to represent a continuous spectrum of phenotypic expression termed J wave syndromes. Despite over 25 years of intensive research, risk stratification and the approach to therapy of these two inherited cardiac arrhythmia syndromes are still rapidly evolving. Our objective in this review is to provide an integrated synopsis of the clinical characteristics, risk stratifiers, as well as the molecular, ionic, cellular, and genetic mechanisms underlying these two syndromes that have captured the interest and attention of the cardiology community over the past two decades.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Brugada syndrome; cardiac arrhythmias; early repolarization syndrome; inherited cardiac arrhythmias syndrome; sudden cardiac death; ventricular fibrillation; ventricular tachycardia

Mesh:

Year:  2018        PMID: 29870068      PMCID: PMC6281786          DOI: 10.1111/pace.13408

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  194 in total

1.  Androgens and male predominance of the Brugada syndrome phenotype.

Authors:  Charles Antzelevitch
Journal:  Pacing Clin Electrophysiol       Date:  2003-07       Impact factor: 1.976

2.  Prominent J wave and ST segment elevation: serial electrocardiographic changes in accidental hypothermia.

Authors:  Takashi Noda; Wataru Shimizu; Kouichi Tanaka; Kazuaki Chayama
Journal:  J Cardiovasc Electrophysiol       Date:  2003-02

3.  The electrocardiogram in hypothermia-the J wave and the Brugada syndrome.

Authors:  Basil M RuDusky
Journal:  Am J Cardiol       Date:  2004-03-01       Impact factor: 2.778

4.  Coexisting early repolarization pattern and Brugada syndrome: recognition of potentially overlapping entities.

Authors:  William F McIntyre; Andrés Ricardo Pérez-Riera; Francisco Femenía; Adrian Baranchuk
Journal:  J Electrocardiol       Date:  2011-12-16       Impact factor: 1.438

5.  KCNE5 (KCNE1L) variants are novel modulators of Brugada syndrome and idiopathic ventricular fibrillation.

Authors:  Seiko Ohno; Dimitar P Zankov; Wei-Guang Ding; Hideki Itoh; Takeru Makiyama; Takahiro Doi; Satoshi Shizuta; Tetsuhisa Hattori; Akashi Miyamoto; Nobu Naiki; Jules C Hancox; Hiroshi Matsuura; Minoru Horie
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-04-14

6.  Electrical storm in Brugada syndrome successfully treated with orciprenaline; effect of low-dose quinidine on the electrocardiogram.

Authors:  Konstantinos Kyriazis; Edda Bahlmann; Hendrik van der Schalk; Karl-Heinz Kuck
Journal:  Europace       Date:  2009-04-03       Impact factor: 5.214

Review 7.  The Early Repolarization Pattern: A Consensus Paper.

Authors:  Peter W Macfarlane; Charles Antzelevitch; Michel Haissaguerre; Heikki V Huikuri; Mark Potse; Raphael Rosso; Frederic Sacher; Jani T Tikkanen; Hein Wellens; Gan-Xin Yan
Journal:  J Am Coll Cardiol       Date:  2015-07-28       Impact factor: 24.094

Review 8.  Genetic, molecular and cellular mechanisms underlying the J wave syndromes.

Authors:  Charles Antzelevitch
Journal:  Circ J       Date:  2012-04-11       Impact factor: 2.993

9.  Outcome after implantation of cardioverter defibrillator [corrected] in patients with Brugada syndrome: a multicenter Israeli study (ISRABRU).

Authors:  Raphael Rosso; Aharon Glick; Michael Glikson; Abraham Wagshal; Moshe Swissa; Shimon Rosenhek; Israel Shetboun; Vladimir Khalamizer; Therese Fuchs; Munther Boulos; Michael Geist; Boris Strasberg; Michael Ilan; Bernard Belhassen
Journal:  Isr Med Assoc J       Date:  2008-06       Impact factor: 0.892

10.  Mechanisms underlying the development of the electrocardiographic and arrhythmic manifestations of early repolarization syndrome.

Authors:  István Koncz; Zsolt Gurabi; Bence Patocskai; Brian K Panama; Tamás Szél; Dan Hu; Hector Barajas-Martínez; Charles Antzelevitch
Journal:  J Mol Cell Cardiol       Date:  2013-12-28       Impact factor: 5.000

View more
  5 in total

1.  Predictive effect of J waves on cardiac compression and clinical prognosis of esophageal tumors: a retrospective study.

Authors:  Songcui Shen; Yichen Xie; Pengliang Ju; Wenzhao Li; Jiayuan Zhang; Ruxin Cai; Ruogu Li
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Distinct Features of Probands With Early Repolarization and Brugada Syndromes Carrying SCN5A Pathogenic Variants.

Authors:  Zhong-He Zhang; Hector Barajas-Martínez; Hao Xia; Bian Li; John A Capra; Jerome Clatot; Gan-Xiao Chen; Xiu Chen; Bo Yang; Hong Jiang; Gary Tse; Yoshiyasu Aizawa; Michael H Gollob; Melvin Scheinman; Charles Antzelevitch; Dan Hu
Journal:  J Am Coll Cardiol       Date:  2021-10-19       Impact factor: 27.203

Review 3.  Electrophysiological Basis for Early Repolarization Syndrome.

Authors:  Rubén Casado Arroyo; Juan Sieira; Maciej Kubala; Decebal Gabriel Latcu; Shigo Maeda; Pedro Brugada
Journal:  Front Cardiovasc Med       Date:  2018-11-06

4.  Inter-Regulation of Kv4.3 and Voltage-Gated Sodium Channels Underlies Predisposition to Cardiac and Neuronal Channelopathies.

Authors:  Jérôme Clatot; Nathalie Neyroud; Robert Cox; Charlotte Souil; Jing Huang; Pascale Guicheney; Charles Antzelevitch
Journal:  Int J Mol Sci       Date:  2020-07-17       Impact factor: 5.923

5.  Susceptibility to Ventricular Arrhythmias Resulting from Mutations in FKBP1B, PXDNL, and SCN9A Evaluated in hiPSC Cardiomyocytes.

Authors:  Hector Barajas-Martinez; Maya Smith; Dan Hu; Robert J Goodrow; Colleen Puleo; Can Hasdemir; Charles Antzelevitch; Ryan Pfeiffer; Jacqueline A Treat; Jonathan M Cordeiro
Journal:  Stem Cells Int       Date:  2020-09-01       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.